UMIN-CTR Clinical Trial

Recruitment status Terminated
Unique ID issued by UMIN UMIN000011752
Receipt No. R000013739
Official scientific title of the study Prospective, randomized, open-label, clinical trial evaluating the effects of dipeptidyl peptidase-4 (DPP4) inhibitors on progression of atherosclerotic plaques and endothelial function in type 2 diabetic patients
Date of disclosure of the study information 2013/09/14
Last modified on 2018/05/24 (Ver. 2)

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information
Official scientific title of the study Prospective, randomized, open-label, clinical trial evaluating the effects of dipeptidyl peptidase-4 (DPP4) inhibitors on progression of atherosclerotic plaques and endothelial function in type 2 diabetic patients
Title of the study (Brief title) Clinical trial evaluating the effects of dipeptidyl peptidase-4 (DPP4) inhibitors
Region
Japan

Condition
Condition type 2 diabetes
Classification by specialty
Endocrinology and Metabolism
Classification by malignancy Others
Genomic information NO

Objectives
Narrative objectives1 To compare therapies with or without DPP4 inhibotors on atherosclerotic plaques progression and endothelial function in type 2 diabetic patients
Basic objectives2 Efficacy
Basic objectives -Others
Trial characteristics_1
Trial characteristics_2
Developmental phase

Assessment
Primary outcomes (1) Area and thickness of atherosclerotic plaques in aorta detected by magnetic resonance imaging (MRI)
12/24 months after randomization
(2) Flow-mediated vasodilation in forearm
6 months after randomization
Key secondary outcomes (1) Ankle/brachial index and cardio ankle vascular index
(2) Markers for diabetes (hemoglobin A1c, glycoalbumin, blood glucose)
(3) Serum lipids
(4) Markers indicating obesity (e.g. adiponectin)
(5) Markers indicating inflammation (e.g. high sensitive CRP)
(6) Markers indicating oxidative stress (8-OHdG/ MDA-LDL)
(7) Markers indicating chronic renal diseases (urine albumin/L-FABP)
(8) Blood/urine urate levels
(9) Body weight/waist circumference
(10) blood pressures

Base
Study type Interventional

Study design
Basic design Parallel
Randomization Randomized
Randomization unit
Blinding Open -no one is blinded
Control Active
Stratification
Dynamic allocation
Institution consideration
Blocking
Concealment

Intervention
No. of arms 2
Purpose of intervention Treatment
Type of intervention
Medicine
Interventions/Control_1 Treatment for type 2 diabetes with DPP4 inhibitors
Interventions/Control_2 Treatment for type 2 diabetes without DPP4 inhibitors
Interventions/Control_3
Interventions/Control_4
Interventions/Control_5
Interventions/Control_6
Interventions/Control_7
Interventions/Control_8
Interventions/Control_9
Interventions/Control_10

Eligibility
Age-lower limit
20 years-old <=
Age-upper limit
80 years-old >
Gender Male and Female
Key inclusion criteria 1) Type 2 diabetic patients who should be treated with anti-diabetic agents recommended by Japan Diabetes Society Guidelines
2) Patients who have aortic atherosclerotic plaques detected by MRI
3) Outpatients
4) Subjects who gave written informed consent
Key exclusion criteria 1) Allergy against DPP4 inhibitors
2) Type 1 diabetes or patients with positive anti-islet antibodies
3) Secondary diabetes
4) Poor-controlled diabetes (HbA1c>10.0 %)
5) Under administration of DPP-4 inhibitors or GLP-1 agonists
6) History of stroke, acute coronary syndrome or any cardiovascular diseases needed for inpatient-treatments within 6 months
7) Either level of aspartate aminotransaminase or alanine aminotransferase exceeds three-fold of the normal limits
8) End stage renal disease
9) Symptomatic (NYHA III or IV) congestive heart failure
10) Malignancies or other diseases with poor prognosis
11) Pregnant
12) Subjects whose doctor in charge do not agree to join the trial
Target sample size 66

Research contact person
Name of lead principal investigator Katsunori Ikewaki
Organization National Defense Medical College
Division name Department of Internal Medicine
Address 3-2 Namiki, Tokorozawa, JAPAN 359-8513
TEL 04-2995-1617
Email katsunorike@ndmc.ac.jp

Public contact
Name of contact person Makoto Ayaori
Organization National Defense Medical College
Division name Department of Internal Medicine
Address 3-2 Namiki, Tokorozawa, JAPAN 359-8513
TEL 04-2995-1617
Homepage URL
Email ayaori@ndmc.ac.jp

Sponsor
Institute National Defense Medical College
Institute
Department

Funding Source
Organization Foundation for Promotion of Defense Medicine
Organization
Division
Category of Funding Organization Non profit foundation
Nationality of Funding Organization

Other related organizations
Co-sponsor
Name of secondary funder(s)

Secondary IDs
Secondary IDs NO
Study ID_1
Org. issuing International ID_1
Study ID_2
Org. issuing International ID_2
IND to MHLW

Institutions
Institutions

Other administrative information
Date of disclosure of the study information
2013 Year 09 Month 14 Day

Progress
Recruitment status Terminated
Date of protocol fixation
2013 Year 07 Month 30 Day
Anticipated trial start date
2013 Year 09 Month 14 Day
Last follow-up date
Date of closure to data entry
Date trial data considered complete
Date analysis concluded

Related information
URL releasing protocol
Publication of results Unpublished
URL releasing results
Results
Other related information

Management information
Registered date
2013 Year 09 Month 13 Day
Last modified on
2018 Year 05 Month 24 Day


Link to view the page
URL(English) https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000013739